INNOCAN PHARMA CORP (INNPF)
News Quantified tracks INNPF headlines — 131 labeled events over the last three years — but too few produced usable price reactions to publish stable medians. The events themselves are below.
Not enough usable reactions to publish INNPF medians.
131 INNPF events are labeled, but too few carry a measurable price reaction for a median to mean anything. When enough reactions accumulate, the medians publish here the same way as every other name.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when INNPF moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to INNPF's baseline. Nothing else.
Recent INNPF events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Innocan Pharma Announces Closing of Additional Debenture | Press release | Canada Newswire | — | — | |
| Innocan Pharma Announces Offering of an Additional Debenture to Tamar Innovest | Press release | Canada Newswire | — | — | |
| Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M | Press release | Canada Newswire | — | — | |
| Innocan Pharma Announces Closing of a Debenture to its Largest Shareholder, Tamar Innovest | Press release | Canada Newswire | — | — | |
| Innocan Pharma Announces Offering of a Debenture to its Largest Shareholder, Tamar Innovest | Press release | Canada Newswire | — | — | |
| Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering | Press release | PR Newswire | +0.00% | +0.00% | |
| Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering | Press release | PR Newswire | +0.00% | +0.00% | |
| Innocan Pharma Announces Public Filing of Amended Registration Statement for Proposed U.S. Public Offering | Press release | Canada Newswire | — | — | |
| Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M | Press release | Canada Newswire | — | — | |
| Innocan Pharma to Present at the 2025 ThinkEquity Conference | Press release | Canada Newswire | — | — | |
| Liposomal CBD Injection Technology (LPT-CBD) patent was allowed in Japan | Press release | Canada Newswire | +0.00% | +0.00% | |
| Innocan Pharma Partners With a Sanctuary For Injured Animals to Bring Remedy and Hope with its LPT-CBD injection | Press release | Canada Newswire | — | — | |
| Innocan Pharma's Poster on its Liposomal Synthetic CBD Technology Generates Interest at PAINWeek Conference | Press release | Canada Newswire | — | — | |
| Form F-1/A INNOCAN PHARMA Corp | SEC filing · Form F-1 | SEC EDGAR | — | — | |
| Innocan Pharma Announces Details of Proposed Share Consolidation | Press release | Canada Newswire | — | — | |
| Innocan Pharma Announces First Half Of 2025 Financial Results | Press release | Canada Newswire | — | — | |
| Innocan's Findings to be Showcased in Scientific Poster Reception at PAINWeek 2025 Conference in Las Vegas, Nevada | Press release | Canada Newswire | — | — | |
| Form F-1/A INNOCAN PHARMA Corp | SEC filing · Form F-1 | SEC EDGAR | — | — | |
| Form F-1 INNOCAN PHARMA Corp | SEC filing · Form F-1 | SEC EDGAR | — | — | |
| Innocan Pharma Announces Public Filing of Registration Statement for Proposed U.S. Public Offering | Press release | Canada Newswire | — | — | |
| Innocan Pharma Announces Promising Results of LPT-CBD Administered to Gottingen Minipigs, providing a good translational model and Provides Corporate Update | Press release | Canada Newswire | — | — | |
| Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference | Press release | Canada Newswire | — | — | |
| Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic CBD for Chronic Pain: A Novel Non-Opioid Analgesic Approach | Press release | Canada Newswire | — | — | |
| Innocan Pharma Announces First Quarter 2025 Financial Results with Continued Strong Revenue Growth and Provides Corporate Update | Press release | Canada Newswire | — | — | |
| Innocan Pharma First Granted Patent in Mexico for its Topical Pain Relief | Press release | Canada Newswire | — | — | |
| Innocan Pharma Announces Closing of Private Placement | Press release | Canada Newswire | — | — | |
| Innocan Pharma Broadens Intellectual Property Coverage for its Liposomal CBD Injection Across Asia and Announces Private Placement of Units | Press release | Canada Newswire | — | — | |
| Innocan Pharma Reports Full Year 2024 Results with Revenues more than Doubling to US $29.4 million | Press release | Canada Newswire | — | — | |
| Innocan Pharma Announces Closing of Debenture Unit Offering to its Largest Shareholder, Tamar Innovest Limited | Press release | Canada Newswire | — | — | |
| Innocan Pharma Announces Private Placement Offering of a Debenture Unit to its Largest Shareholder, Tamar Innovest | Press release | Canada Newswire | — | — | |
| Innocan Pharma's Liposomal CBD Injection Shows Breakthrough Pain Relief in Elderly Donkey with Osteoarthritis | Press release | Canada Newswire | — | — | |
| Innocan Pharma's Subsidiary BI Sky Global Completes HRIPT Testing and Surpasses Important Sales Milestone | Press release | Canada Newswire | — | — | |
| FDA's Center for Veterinary Medicine Grants Innocan Pharma a Fee Waiver for 2025 | Press release | Canada Newswire | — | — | |
| Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of C$635,444.60 | Press release | Canada Newswire | — | — | |
| Innocan Pharma Announces Private Placement of Units | Press release | Canada Newswire | — | — | |
| Innocan Pharma Provides its Annual "State of Research and Development" Update for 2024 | Press release | Canada Newswire | — | — | |
| Innocan Pharma Announces Encouraging Results from a Safety Assessment Study of LPT-CBD on Minipigs | Press release | Canada Newswire | — | — | |
| Innocan Pharma Reports Third Quarter 2024 Financial Results | Press release | Canada Newswire | — | — | |
| Innocan to Direct Full Focus on Following Positive FDA Engagement and Significant Potential Market Demand | Press release | Canada Newswire | — | — | |
| Innocan Pharma to Present at the 2024 ThinkEquity Conference | Press release | GlobeNewswire | — | — | |
| Innocan Pharma to Participate at the ThinkEquity 2024 Investor Conference in New York Also Announces Relaunch of Updated Website for Enhanced Investor Experience | Press release | Canada Newswire | — | — | |
| Innocan Pharma's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs | Press release | Canada Newswire | — | — | |
| Innocan Pharma Celebrates Dr. Joseph Pergolizzi's Recognition Among Stanford University's List of the Top 2% Most-Cited Scientists Worldwide | Press release | Canada Newswire | +0.00% | +0.00% | |
| Innocan Pharma Advances Liposomal CBD with Positive Response from FDA Following Successful Pre-IND Meeting | Press release | Canada Newswire | — | — | |
| Innocan Pharma Announces Closing of Private Placement and Grant of Stock Options | Press release | Canada Newswire | — | — | |
| Innocan Pharma's Subsidiary BI Sky Global Successfully Completes FDA MoCRA Registration | Press release | Canada Newswire | +0.00% | +0.00% | |
| Innocan Pharma Reports Second Quarter 2024 Results with Revenue Growth of over 2.8X to $8.6 Million | Press release | Canada Newswire | +0.00% | +0.00% | |
| Innocan Pharma Submits Investigational New Animal Drug Application to FDA's Veterinary Center | Press release | Canada Newswire | — | — | |
| Innocan Pharma Engages Pain Management Expert in Preparation for Upcoming FDA Meeting | Press release | Canada Newswire | — | — | |
| Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs | Press release | Canada Newswire | — | — |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the INNPF section they belong to.
Where else INNPF is measured.
INNPF earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.